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CHAPTER 8
Is high-sensitive C-reactive protein
















Functional somatic symptoms (FSS) are symptoms unexplained in terms of underlying 
organic pathology. Alterations in the immune system function may be associated with 
FSS via induction of sickness behavior. We aimed to investigate whether low-grade 
immune system activation is positively associated with FSS in a population-based 
cohort of 881 adults (46% male, mean age 53.0, SD11.4). Participants completed the 
somatization section of the Composite International Diagnostic Interview surveying the 
presence of 43 FSS. Innate immune function was assessed by measuring high-sensitive 
C-reactive protein (hs-CRP). Follow-up measurements of hs-CRP and FSS were 
performed approximately 2 years later. Regression analyses, with adjustments for 
gender, age, body mass index, anxiety, depression, smoking, alcohol use, and frequency 
of exercise, did not reveal a cross-sectional association (ȕ = 0.01, t = 0.40, p = 0.693) 
or longitudinal association (ȕ = -0.03, t = -0.93, p = 0.352) between hs-CRP and the 
total number of FSS. When examining different bodily clusters of FSS, hs-CRP was not 
associated with the gastrointestinal FSS cluster, but the association approached 
statistical significance for the general FSS cluster (OR 1.08, 95% CI 0.98 to 1.18) and 
musculoskeletal FSS cluster (OR 1.08, 95% CI 0.99 to 1.17). For the latter association, 
exploratory analyses revealed that mainly the pure musculoskeletal complaints were 
responsible (OR 1.12, 95% CI 1.03 to 1.21). We conclude that the level of hs-CRP is not 
a biomarker for the total number of FSS in the general population. The association 
between hs-CRP and musculoskeletal and general FSS needs further study.  
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INTRODUCTION 
Functional somatic symptoms (FSS), symptoms unexplained by underlying 
organic pathology, are multifactorially caused (Mayou & Farmer 2002). 
Functional somatic disorders (FSD), such as chronic fatigue syndrome, 
fibromyalgia, and irritable bowel syndrome, can be regarded as clusters of several 
FSS and are likely to share a common etiology (Wessely et al. 1999). Virtually all 
explanatory models on the etiology of FSS and FSD assign a role for psychosocial 
stress (Deary et al. 2007). One of the psychobiological mechanisms that may link 
psychosocial stress to FSS is the immune system (Segerstrom & Miller 2004).  
Different pathways may be etiologically involved in this link. Firstly, the immune 
system may be related to FSS via sickness behavior, a constellation of non-
specific symptoms induced by pro-inflammatory cytokines, such as interleukin 
(IL)-1, IL-6, and tumor necrosis factor (TNF)-Į (Dantzer 2001, Wieseler-Frank et 
al. 2005). These non-specific sickness behavior symptoms, including fatigue, 
weakness, malaise, hyperalgesia, and increased focus on own body, are core 
characteristics of persons having FSS and FSD (Dantzer 2005). Secondly, 
immune activation may be a marker for activation of other stress responsive 
systems that are possibly involved in FSS and FSD, namely, the autonomic 
nervous system and the hypothalamic-pituitary-adrenal axis (Heim et al. 2000a, 
Tak & Rosmalen 2007), as both systems closely interact with the immune system 
(McEwen et al. 1997, Araujo et al. 2006).  
Indeed, numerous abnormalities in immune cell quantity and function have been 
identified in several FSD (Klimas & Koneru 2007, Liebregts et al. 2007). However, 
those abnormalities are rarely replicated, which is illustrated by a critical review on 
immunological abnormalities in chronic fatigue syndrome (Lyall et al. 2003). 
Furthermore, a study combining patients with different FSD did not find 
differences in pro- and anti-inflammatory cytokines between patients and healthy 
controls (Houtveen et al. 2007a). These inconsistent findings may be due to the 
fact that relevant alterations in central cytokine levels, if present, are not 
adequately reflected in peripheral blood measurements (Dantzer 2001).  
IL-6 and TNF-Į have a central role in stimulating the liver to produce C-reactive 
protein (CRP), which might be a more integrated and accurate peripheral marker 
for innate immune system activation. CRP is a particularly suitable measure for 
large epidemiological studies because assessment is relatively easy and reference 
values are known. Although historically long been considered as clinically 
irrelevant, minor elevations of CRP (3 - 10 mg/L) have been reported to be 
associated with psychosocial stress (McDade et al. 2006) and a variety of somatic 
as well as psychiatric conditions (Kushner et al. 2006). Ultrasensitive assays can 
detect CRP in this subclinical range as high-sensitive CRP (hs-CRP). Of 
associations of circulating concentrations of CRP and pro-inflammatory cytokines 
Chapter 8 
140 
in subjects of the general population without active infection, those between IL-6 
and CRP have been most frequently investigated and are generally strongest, with 
reported significant correlation coefficients ranging from 0.24 to 0.50 (Ridker et 
al. 2000, Cesari et al. 2003, Piche et al. 2005, Berrahmoune et al. 2007, Stewart et 
al. 2008, Milaneschi et al. 2009). In the study with the strongest correlation 
between IL-6 and CRP, which included 991 subjects aged 65 years and older, 
correlations of CRP with other investigated cytokines were lower: significant 
correlations of 0.09 and 0.19 were found for IL-1ȕ  and IL-18 respectively, and an 
non-significant correlation of 0.06 was found for TNF-Į (Milaneschi et al. 2009). 
In an elderly population of 2225 subjects, TNF-Į and CRP were found to have a 
weak but significant correlation (correlation coefficient 0.13) (Cesari et al. 2003). 
In smaller studies of 112 postmenopausal women and of 315 adults, correlations 
of TNF-Į with CRP were non-significant (Piche et al. 2005, Berrahmoune et al. 
2007). 
In this study, our hypotheses are that hs-CRP is positively associated with the 
number of FSS in a large population cohort, and that hs-CRP elevations predict 
development of FSS in a two-year follow-up period. Additionally, we explore 




Our study has been performed in a population cohort in Groningen, The 
Netherlands. The selection procedure and sample characteristics have been 
extensively outlined elsewhere (Tak et al. 2009b). Baseline measurements in the 
2001 - 2002 wave were completed by 1094 participants (aged 33 - 79 years). 
Follow-up measurements in the 2003 - 2004 wave were completed by 976 
participants. The study was approved by the local medical ethics committee and 
all subjects gave written consent to participate.  
C-reactive protein  
Fasting blood samples were collected in all participants during a visit to the 
research facilities. In case of flu or a febrile temperature, blood collection was 
postponed to a later time (available blood samples at baseline N = 1024, at 
follow-up N = 983). High-sensitive CRP (hs-CRP) was determined by 
nephelometry with a threshold of 0.18 mg/L and intra- and inter-assay coefficients 
of less than 4.4 and 5.7%, respectively (BNIIN, Dade Behring, Marburg, 
Germany). CRP levels below the detection level were scored as 0.18 mg/L. One-
time measurement is a reliable measure of CRP over an extended period of time 
in healthy individuals (Macy et al. 1997). Since concentrations of CRP increase 
dramatically as part of acute inflammatory response, it has been recommended to 
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discard plasma CRP concentrations above 10 mg/L in studies on CRP as a risk 
factor for cardiovascular disease (Pearson et al. 2003). Likewise, CRP levels above 
10 mg/L may obscure the association between CRP elevations and FSS. Therefore, 
we eliminated subjects with CRP levels above 10 mg/L from our analyses (N = 44 
at baseline, N = 25 at follow-up).  
Functional somatic symptoms  
FSS were measured by the somatization section of the Composite International 
Diagnostic Interview (CIDI), for which the procedure has been outlined elsewhere 
(Tak et al. 2009b). In brief, 43 symptoms are assessed through asking “have you 
had” this symptom. In the CIDI, symptoms are considered present when they 
meet severity criteria, i.e., provoked a health care visit. If these criteria are met, 
the interview assesses in a hierarchical fashion whether a physician diagnosed a 
symptom as due to physical illness or injury, or whether a symptom was caused 
by the use of medication, drugs, or alcohol. If these inquiries are negative for 
medical explanations, the symptom is scored as a FSS. The CIDI has adequate 
test-retest reliability and validity (Andrews & Peters 1998). Participants first 
completed the CIDI lifetime version, measuring lifetime FSS (N = 1088 completed 
CIDIs at baseline). Two years later, participants completed the CIDI 12-months 
version (N = 964 completed CIDIs at follow-up), surveying the same 43 
symptoms in the previous year. As a measure of FSS, we summed all FSS 
reported in the 12-months interview. Furthermore, we created a measure of new-
onset FSS by summing the FSS that were only reported in the 12-months interview 
but not in the lifetime interview.   
Additionally, we constructed bodily clusters of FSS, based on symptom clusters 
previously identified in a large study on the classification of FSS (Fink et al. 2007). 
We generated a cardiopulmonary cluster (including questions about chest pain 
and shortness of breath), a musculoskeletal cluster (including questions about 
back pain, joint pain, pain in extremities, loss of touch or pain sensation, muscle 
weakness, and numbness or tingling sensations), a gastrointestinal cluster 
(including questions about abdominal pain, nausea, diarrhea, feeling bloated or 
flatulence, and food intolerance), and a general symptom cluster (including 
questions about headache, trouble with balance and walking, and dizziness). For 
all clusters, a dichotomous score was generated, with a score of 0 if no FSS in the 
symptom cluster was scored present and a score of 1 if one or more FSS in the 
symptom cluster was scored present.        
                                                                                 
Statistical analysis 
Given the skewed distribution, the number of FSS and new-onset FSS were log-
transformed. We used forced entry linear regression analyses to test whether hs-
CRP was cross-sectionally (using hs-CRP and FSS measured at follow-up) or 
longitudinally (using hs-CRP measured at baseline and FSS measured at follow-
up, adjusted for the number of lifetime FSS) associated with the total number of 
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FSS. Additionally, we tested whether hs-CRP predicted new-onset FSS. 
Standardized E’s are given. Logistic regression analyses were performed to test 
whether hs-CRP is differentially associated with FSS in bodily clusters. Odds ratios 
(OR) and 95% confidence intervals (95% CI) are presented. Gender, age, body 
mass index (BMI), depression, anxiety, smoking, alcohol use, and frequency of 
exercise explain variance in hs-CRP (Visser et al. 1999, Hutchinson et al. 2000, 
Albert et al. 2003, Bazzano et al. 2003, Liukkonen et al. 2006, Lakoski et al. 2006, 
Pitsavos et al. 2006, Kuo et al. 2007) and FSS (Kroenke & Spitzer 1998a, 
Henningsen et al. 2003, Glass et al. 2004, Hasin & Katz 2007, Petry et al. 2008, 
Neumann et al. 2008). Therefore, all regression analyses were adjusted for 
gender, age, BMI, presence of depressive disorder (previous-year diagnosis of 
DSM-IV depressive disorder as assessed by the CIDI), presence of anxiety 
disorder (previous-year diagnosis of DSM-IV panic disorder with or without 
agoraphobia, agoraphobia, general anxiety disorder, and social phobia as 
assessed by the CIDI), smoking (none, 1-5 cigarette(s)/day, 6-10 cigarettes/day, 
11-15 cigarettes/day, 16-20 cigarettes/day, >20 cigarettes/day), alcohol use (none, 
1-4 unit(s)/month, 2-7 units/week, 1-3 unit(s)/day, >3 units/day), and frequency of 
exercise (not/hardly, once per week, twice or more per week). We also present 
results of regression models that are only adjusted for gender and age to illustrate 
the influence of the covariates. Interaction terms of gender with hs-CRP (hs-CRP x 
gender) and age with hs-CRP (hs-CRP x age) were created. All models were 
evaluated for absence of multicollinearity. All analyses were repeated after 
exclusion of participants with medication use (corticosteroids, antihypertensives, 
analgesics, oral contraceptives) or somatic disease (cardiovascular disease, 
rheumatoid arthritis, chronic obstructive pulmonary disease, inflammatory bowel 
disorders, malignancy) that may influence hs-CRP levels. All p-values less than 
0.05 were considered statistically significant.  
 
RESULTS 
At baseline, the mean age of the study population was 53.0 years (SD 11.4), with 
46% males. The median hs-CRP concentration was 1.18 mg/L (interquartile range 
0.55 - 2.58 mg/L). The median number of FSS in the previous year was 1 
(interquartile range 0 - 2 FSS, range in population 0 – 19 FSS). Prevalence of 
having FSS was 6.7% (N = 60) in the cardiorespiratory cluster, 23.7% (N = 227) in 
the musculoskeletal cluster, 12.7% (N = 114) in the gastrointestinal cluster, and 
17.4% (N = 156) in the general cluster. Of the total population, 38.3% developed 
at least one new-onset FSS. 
In the regression models only adjusted for age and gender, no cross-sectional 
association between hs-CRP and the total number of FSS was found (ȕ = 0.05, t = 
1.425,  p = 0.155), nor did hs-CRP predict the total number of FSS (ȕ = -0.01, t = -
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0.38, p = 0.703). After adjustment for several confounders, as shown in Table 1, 
hs-CRP was not associated with the total number of FSS in the cross-sectional 
analysis or in the longitudinal analysis. There were no statistical significant 
interactions of hs-CRP with gender or age (data not shown). Furthermore, hs-CRP 
did not predict the number of new-onset FSS (ȕ -0.03, t = -0.76, p = 0.449).  
Table 1. Multivariable linear regression explaining the number of FSS out of hs-CRP 












Next, we tested whether hs-CRP was differentially associated with FSS in any of 
the bodily clusters (see Table 2). Due to the low number of participants having 
FSS in the cardiorespiratory cluster, this cluster was not suitable for logistic 
regression analyses. In the logistic models only adjusted for gender and age, hs-
CRP was significantly associated with FSS in the musculoskeletal factor. When 
adjusting for several confounders, hs-CRP was not associated with FSS in the 
gastrointestinal cluster, whereas hs-CRP tended to be associated with FSS in the 
general cluster (p = 0.124) and musculoskeletal cluster (p = 0.085). In an 
exploratory analysis, the latter association appeared to be mainly driven by the 
pure musculoskeletal FSS, namely, back pain, joint pain, pain in extremities, and 
muscle weakness (model only adjusted for gender and age OR 1.14, 95% CI 1.06 
to 1.23, z = 11.53, p = 0.001, fully adjusted model OR 1.12, 95% CI 1.03 to 1.21, z = 
6.80, p = 0.009) and not by the more neurological FSS in this factor. Results of 
the longitudinal analyses showed the same positive, although weaker association 




Table 2. Multivariable logistic regression analyses on the association of hs-CRP and 








All analyses were repeated after exclusion of participants with medication use 
(corticosteroids, antihypertensives, analgesics, oral contraceptives) or somatic 
disease (cardiovascular disease, rheumatoid arthritis, chronic obstructive 
pulmonary disease, inflammatory bowel disorders, malignancy) that may 
influence hs-CRP levels. These secondary analyses did not essentially change the 





In this population-based study, we did not find evidence for an association 
between hs-CRP and the total number of FSS. When differentially exploring bodily 
clusters of FSS, hs-CRP tended to be associated with general and (pure) 
musculoskeletal FSS.  
 
To our knowledge, no previous studies addressed hs-CRP and a large range of 
FSS in the general population, however, the few clinical and population-based 
studies that examined hs-CRP in patients with FSD may serve as a reference. In 
line with our findings on FSS in the gastrointestinal bodily cluster, hs-CRP levels 
of patients with irritable bowel syndrome were not different from those of healthy 
controls (Schoepfer et al. 2008). We are unaware of studies specifically focusing 
on musculoskeletal FSS, such as in fibromyalgia, however, hs-CRP was related to 
low back pain in a study in young female adults (Shiri et al. 2008) and self-
reported pain not due to chronic disease in a study in older adults (Graham et al. 
2006). Also in medically explained chronic pain conditions, sickness behavior is 
often considered to be an important contributor to symptom experience. The 
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association between hs-CRP and pure musculoskeletal FSS, which remained after 
exclusion of participants with somatic conditions such as rheumatoid arthritis, is 
in line with previous literature documenting an association between low-grade 
inflammation and chronic pain. The differential associations may be explained by 
the fact that those FSS are related to sickness behavior, mainly to the hyperalgesia 
and weakness components. This idea is supported by studies on chronic fatigue 
syndrome which consistently show that hs-CRP levels are higher in patients 
compared to healthy controls (Buchwald et al. 1997, Spence et al. 2008, Raison et 
al. 2009). Authors of the latter study suggest that this increase in peripheral 
inflammatory signaling might not be specific to chronic fatigue syndrome, but 
apply to unwellness in general. Alternatively, as the association of hs-CRP with 
musculoskeletal FSS became weaker and the association with general FSS 
disappeared in the longitudinal analysis, the association between hs-CRP and 
those FSS may be confounded by conditions or behavior that influence CRP 
levels, such as obesity and depression. Of note, our analyses were adjusted for 
several of such confounders, and hs-CRP remained independently associated with 
pure musculoskeletal FSS. If hs-CRP is a biomarker of those intermediate 
mechanisms, however, this analysis might be over adjusted. We have chosen our 
confounders a priori based on theory, as this strategy will generally constitute 
stronger scientific evidence than models that were achieved in other ways (Babyak 
2004). The drawback of this strategy is inferring that hs-CRP is not causally 
important because its association with FSS is eliminated by the inclusion of 
covariates in the adjustment process, while it may only reflect that the covariates 
treated as confounders are actually critical to the causal chain (Christenfeld et al. 
2004). For example, IL-6 and other pro-inflammatory cytokines are not only 
released by the liver, but have also been shown to be released by adipose tissue 
(Mohamed-Ali et al. 1997, Pou et al. 2007). In this perspective, BMI may not be a 
confounder in the potential relation between hs-CRP and FSS, but rather a causal 
factor inducing low-grade inflammation and sickness behavior. The same kind of 
conceptual problems apply to anxiety, depression, and health behaviors, such as 
regularly being engaged in physical activity. To further disentangle this problem, 
future studies could employ methods that appropriately account for the time-
varying nature of the association by repeatedly assessing hs-CRP, FSS, and 
covariates like BMI, depression, anxiety, and health behaviors, preferably analyzed 
using multi-level statistical techniques (Christenfeld et al. 2004). This type of 
studies has more power to establish whether the association between hs-CRP and 
musculoskeletal FSS is causal, consequential, or epiphenomenonal.  
 
The findings of this our study should be interpreted in light of some limitations. 
First, we only measured hs-CRP, which is a general biomarker for immunological 
activation that may not be sufficient to capture all aspects of immune function. In 
the introduction, we mentioned sickness behavior and activation of stress 
responsive systems as potential links between the immune system and FSS 
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(McEwen et al. 1997, Heim et al. 2000a, Dantzer 2005, Araujo et al. 2006, Tak & 
Rosmalen 2007). Regarding the former, it may be questioned whether hs-CRP is 
an adequate biomarker for sickness behavior in the general population. Current 
evidence for the existence of sickness behavior mainly originates from 
experimental research in animals and research in patients with medically 
explained conditions (Hart 1988, Dantzer et al. 2008a), and has focused on 
cytokines. Pro-inflammatory cytokines that are considered most important in 
sickness behavior are IL̻1ȕ and TNF-Į (Dantzer et al. 2008b), while CRP is more 
strongly associated with IL-6 than with IL-1ȕ and TNF-Į (Ridker et al. 2000, Cesari 
et al. 2003, Piche et al. 2005, Berrahmoune et al. 2007, Stewart et al. 2008, 
Milaneschi et al. 2009). Thus, it cannot be inferred from the current results that 
sickness behavior does not play a role in the experience of FSS in the general 
population. Instead, our negative results might be explained by the fact that hs-
CRP is not a valid indicator for cytokines associated with sickness behavior. 
Second, although the CIDI is a widely-used, validated instrument to diagnose 
somatoform disorders (Andrews & Peters 1998), we have no data on whether 
patients interpreted and recalled the physicians’ opinion correctly. For example, 
headache diagnosed as tension-type headache or muscle pain diagnosed as 
fibromyalgia may be considered as physical illness by the participant. In that case, 
the CIDI will score the symptom as explained by a physical illness and not as FSS. 
We expect that this limitation will result in an underestimation of the true amount 
of FSS in our population, since patients presumably tend to interpret FSS as 
medically explained rather than the opposite (Robins et al. 1982). However, we are 
confident that we have been able to measure FSS with our approach, as the 
female preponderance and the about equally strong associations with anxiety and 
depression are similar to previous studies in the general population (Haug et al. 
2004) and to a study in primary care having involved a physician to decide 
whether symptoms are unexplained (Waal de et al. 2004). Third, we did not take 
into account the severity of the reported FSS. If hs-CRP elevations are only 
associated with FSS that have reached a certain level of severity, our 
measurement of the total number of clinically relevant FSS could have diluted this 
association. The major strength of this study is its large cohort and extensive data 
collection, providing the possibility to adjust for several confounders.  
In conclusion, we did not find evidence for a relationship between hs-CRP levels 
and the total number of FSS in the general population. Intriguingly, hs-CRP seems 
differentially related to pure musculoskeletal FSS. This finding needs further 
attention in future studies that are designed to gain more insight in which 
variables should be considered as confounders, which as mediators, and which as 
moderators. 
